HUP0401351A3 - Pharmaceutical compositions comprising polysaccharide conjugates for inhibiting the metastsis or preventing the recurrence ofmaligant tumor - Google Patents
Pharmaceutical compositions comprising polysaccharide conjugates for inhibiting the metastsis or preventing the recurrence ofmaligant tumorInfo
- Publication number
- HUP0401351A3 HUP0401351A3 HU0401351A HUP0401351A HUP0401351A3 HU P0401351 A3 HUP0401351 A3 HU P0401351A3 HU 0401351 A HU0401351 A HU 0401351A HU P0401351 A HUP0401351 A HU P0401351A HU P0401351 A3 HUP0401351 A3 HU P0401351A3
- Authority
- HU
- Hungary
- Prior art keywords
- ofmaligant
- metastsis
- recurrence
- tumor
- inhibiting
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title 1
- 150000004676 glycans Chemical class 0.000 title 1
- 230000002401 inhibitory effect Effects 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 229920001282 polysaccharide Polymers 0.000 title 1
- 239000005017 polysaccharide Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Oncology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2001249717 | 2001-08-21 | ||
| PCT/JP2002/008309 WO2003015826A1 (en) | 2001-08-21 | 2002-08-16 | Pharmaceutical compositions comprising polysaccharide conjugates for inhibiting the metastsis or preventing the recurrence of maligant tumor |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| HUP0401351A2 HUP0401351A2 (en) | 2004-12-28 |
| HUP0401351A3 true HUP0401351A3 (en) | 2011-02-28 |
Family
ID=19078678
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HU0401351A HUP0401351A3 (en) | 2001-08-21 | 2002-08-16 | Pharmaceutical compositions comprising polysaccharide conjugates for inhibiting the metastsis or preventing the recurrence ofmaligant tumor |
Country Status (18)
| Country | Link |
|---|---|
| EP (1) | EP1418947A1 (en) |
| KR (1) | KR20040027972A (en) |
| CN (1) | CN100372570C (en) |
| AR (1) | AR035137A1 (en) |
| AU (1) | AU2002328093B2 (en) |
| BR (1) | BR0212036A (en) |
| CA (1) | CA2457056C (en) |
| HU (1) | HUP0401351A3 (en) |
| IL (1) | IL160148A0 (en) |
| MX (1) | MXPA04001599A (en) |
| NO (1) | NO20041194L (en) |
| NZ (1) | NZ530947A (en) |
| PL (1) | PL368319A1 (en) |
| RU (1) | RU2275913C2 (en) |
| TW (1) | TWI313609B (en) |
| UA (1) | UA75450C2 (en) |
| WO (1) | WO2003015826A1 (en) |
| ZA (1) | ZA200400917B (en) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW200306314A (en) * | 2002-04-16 | 2003-11-16 | Tanabe Seiyaku Co | Liquid preparation comprising camptothecin derivative and pharmaceutical composition producible by lyophilizing the preparation |
| RU2283848C1 (en) * | 2005-06-16 | 2006-09-20 | Институт нефтехимии и катализа РАН Республика Башкортостан | Method for production of alginic acid conjugates |
| FR2914305B1 (en) | 2007-03-29 | 2009-07-03 | Proteins & Peptides Man | DEXTRAN FUNCTIONALIZED BY HYDROPHOBIC AMINO ACIDS |
| RU2320334C1 (en) * | 2006-08-07 | 2008-03-27 | Государственное образовательное учреждение высшего профессионального образования "Нижегородская государственная медицинская академия Федерального Агентства по здравоохранению и социальному развитию" (ГОУ ВПО НижГМА Росздрава) | Preparation for inhibiting tumor growth and method for inhibiting tumor growth in experiment |
| RU2359975C2 (en) * | 2007-04-04 | 2009-06-27 | Институт нефтехимии и катализа РАН | Method for production of modified arabinogalactan |
| KR102355820B1 (en) | 2008-07-16 | 2022-02-08 | 칠드런'즈 메디컬 센터 코포레이션 | Organ mimic device with microchannels and methods of use and manufacturing thereof |
| KR20190042747A (en) * | 2011-06-02 | 2019-04-24 | 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 | Methods and uses for ex vivo tissue culture systems |
| PL221351B1 (en) | 2012-03-14 | 2016-03-31 | Politechnika Warszawska | Method for obtaining polysaccharide nanoparticles |
| BR112015006521B1 (en) * | 2012-10-11 | 2022-03-03 | Daiichi Sankyo Company, Limited | ANTIBODY-DRUG CONJUGATE, ITS PREPARATION METHOD AND USE, DRUGS AND PHARMACEUTICAL COMPOSITION |
| ES2782248T3 (en) * | 2012-10-19 | 2020-09-11 | Daiichi Sankyo Co Ltd | Antibody-drug conjugate produced by binding through a linker having a hydrophilic structure |
| KR102190548B1 (en) | 2014-01-31 | 2020-12-14 | 다이이찌 산쿄 가부시키가이샤 | Anti-her2 antibody-drug conjugate |
| AU2016258284C1 (en) | 2015-05-04 | 2020-09-03 | Pfizer Inc. | Group B Streptococcus polysaccharide-protein conjugates, methods for producing conjugates, immunogenic compositions comprising conjugates, and uses thereof |
| BR112017027690A2 (en) | 2015-06-29 | 2018-10-09 | Daiichi Sankyo Co Ltd | “method for producing an antibody-drug conjugate composition, and antibody-drug conjugate composition |
| WO2018110515A1 (en) | 2016-12-12 | 2018-06-21 | 第一三共株式会社 | Combination of antibody-drug conjugate and immune checkpoint inhibitor |
| IL268102B2 (en) | 2017-01-17 | 2024-12-01 | Daiichi Sankyo Co Ltd | Anti-gpr20 antibody and anti-gpr20 antibody-drug conjugate |
| TWI794230B (en) | 2017-05-15 | 2023-03-01 | 日商第一三共股份有限公司 | Anti cdh6 antibodies and anti cdh6 antibody drug conjugates, as well as manufacturing method thereof |
| CN117838880A (en) | 2017-08-31 | 2024-04-09 | 第一三共株式会社 | New method for preparing antibody-drug conjugates |
| SG11202000997YA (en) | 2017-08-31 | 2020-03-30 | Daiichi Sankyo Co Ltd | Improved method for producing antibody-drug conjugate |
| KR20210013107A (en) | 2018-05-18 | 2021-02-03 | 다이이찌 산쿄 가부시키가이샤 | Anti-MUC1 antibody-drug conjugate |
| CA3107732A1 (en) | 2018-07-27 | 2020-01-30 | Daiichi Sankyo Company, Limited | Protein recognizing drug moiety of antibody-drug conjugate |
| EA202190403A1 (en) | 2018-07-31 | 2021-05-24 | Дайити Санкио Компани, Лимитед | TREATMENT OF METASTATIC BRAIN TUMOR BY INJECTING AN ANTIBODY-DRUG CONJUGATE |
| CN109481691A (en) * | 2018-11-20 | 2019-03-19 | 珠海天香苑生物科技发展股份有限公司 | Gemcitabine-carboxymethyl polysaccharide conjugate, preparation method and its usage |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE69425464T2 (en) * | 1993-02-26 | 2001-05-23 | Drug Delivery System Institute, Ltd. | POLYSACCHARIDE DERIVATIVE AND ACTIVE SUBSTANCE |
| SG50747A1 (en) * | 1995-08-02 | 1998-07-20 | Tanabe Seiyaku Co | Comptothecin derivatives |
| CA2192725C (en) * | 1995-12-28 | 2004-04-20 | Kenji Tsujihara | Camptothecin derivatives |
| ATE310538T1 (en) * | 1996-04-15 | 2005-12-15 | Asahi Chemical Ind | MEDICINAL COMPLEXES CONTAINING TAXANE COMPOUNDS OR STEROIDS |
| TW527183B (en) * | 1996-06-06 | 2003-04-11 | Daiichi Seiyaku Co | Drug complex |
| CN1058038C (en) * | 1996-12-31 | 2000-11-01 | 中国科学院感光化学研究所 | Low contract photo-solidification cladding material, its prepn. method and use |
| EA003398B1 (en) * | 1998-05-22 | 2003-04-24 | Дайити Фармасьютикал Ко., Лтд. | Drug complex with polymeric carrier |
-
2002
- 2002-08-14 TW TW091118260A patent/TWI313609B/en not_active IP Right Cessation
- 2002-08-15 AR ARP020103077A patent/AR035137A1/en unknown
- 2002-08-16 AU AU2002328093A patent/AU2002328093B2/en not_active Ceased
- 2002-08-16 CN CNB028163176A patent/CN100372570C/en not_active Expired - Fee Related
- 2002-08-16 WO PCT/JP2002/008309 patent/WO2003015826A1/en active IP Right Grant
- 2002-08-16 HU HU0401351A patent/HUP0401351A3/en unknown
- 2002-08-16 UA UA2004032071A patent/UA75450C2/en unknown
- 2002-08-16 EP EP02762786A patent/EP1418947A1/en not_active Withdrawn
- 2002-08-16 NZ NZ530947A patent/NZ530947A/en not_active IP Right Cessation
- 2002-08-16 KR KR10-2004-7002566A patent/KR20040027972A/en not_active Ceased
- 2002-08-16 RU RU2004108141/15A patent/RU2275913C2/en not_active IP Right Cessation
- 2002-08-16 IL IL16014802A patent/IL160148A0/en unknown
- 2002-08-16 CA CA002457056A patent/CA2457056C/en not_active Expired - Fee Related
- 2002-08-16 MX MXPA04001599A patent/MXPA04001599A/en unknown
- 2002-08-16 BR BR0212036-4A patent/BR0212036A/en not_active IP Right Cessation
- 2002-08-16 PL PL02368319A patent/PL368319A1/en not_active Application Discontinuation
-
2004
- 2004-02-04 ZA ZA200400917A patent/ZA200400917B/en unknown
- 2004-03-19 NO NO20041194A patent/NO20041194L/en not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| NZ530947A (en) | 2006-04-28 |
| AR035137A1 (en) | 2004-04-14 |
| RU2275913C2 (en) | 2006-05-10 |
| RU2004108141A (en) | 2005-04-20 |
| WO2003015826A1 (en) | 2003-02-27 |
| CN100372570C (en) | 2008-03-05 |
| BR0212036A (en) | 2004-08-17 |
| PL368319A1 (en) | 2005-03-21 |
| EP1418947A1 (en) | 2004-05-19 |
| KR20040027972A (en) | 2004-04-01 |
| HUP0401351A2 (en) | 2004-12-28 |
| UA75450C2 (en) | 2006-04-17 |
| TWI313609B (en) | 2009-08-21 |
| CA2457056C (en) | 2008-07-22 |
| MXPA04001599A (en) | 2004-07-08 |
| AU2002328093B2 (en) | 2005-05-05 |
| CN1545423A (en) | 2004-11-10 |
| IL160148A0 (en) | 2004-07-25 |
| NO20041194L (en) | 2004-03-19 |
| CA2457056A1 (en) | 2003-02-27 |
| ZA200400917B (en) | 2004-08-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HUP0401351A3 (en) | Pharmaceutical compositions comprising polysaccharide conjugates for inhibiting the metastsis or preventing the recurrence ofmaligant tumor | |
| ZA200208163B (en) | Pharmaceutical compositions comprising fluvastatin. | |
| HUP0202513A3 (en) | Betha-carboline pharmaceutical compositions | |
| ZA200003998B (en) | Pharmaceutical compositions. | |
| GB0028088D0 (en) | Pharmaceutical compositions | |
| GB0001662D0 (en) | Pharmaceutical compositions | |
| GB9916536D0 (en) | Nutritional or pharmaceutical compositions | |
| MXPA01010676A (en) | Pharmaceutical composition. | |
| GB0111597D0 (en) | Pharmaceutical compositions | |
| IL145290A0 (en) | Pharmaceutical compositions comprising complexes | |
| GB9923436D0 (en) | Pharmaceutical compositions | |
| ZA200210359B (en) | Pharmaceutical compositions. | |
| ZA200000857B (en) | Pharmaceutical composition. | |
| GB9904163D0 (en) | Pharmaceutical compositions | |
| MXPA03002105A (en) | Pharmaceutical compositions. | |
| GB9911017D0 (en) | Pharmaceutical compositions | |
| GB0104752D0 (en) | Pharmaceutical compositions | |
| GB9904911D0 (en) | Pharmaceutical compositions | |
| HUP0200253A3 (en) | Pharmaceutical compositions for combination therapy | |
| GB2382302B (en) | Pharmaceutical compositions | |
| GB9902651D0 (en) | Pharmaceutical compositions | |
| ZA200110500B (en) | Pharmaceutical composition. | |
| MXPA03007318A (en) | Pharmaceutical composition. | |
| HK1065958A (en) | Pharmaceutical compositions comprising polysaccharide conjugates for inhibiting the metastasis or preventing the recurrence of malignant tumor | |
| ZA200110501B (en) | Pharmaceutical composition. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| GB9A | Succession in title |
Owner name: MITSUBISHI TANABE PHARMA CORPORATION, JP Free format text: FORMER OWNER(S): TANABE SEIYAKU CO., LTD., JP |
|
| FD9A | Lapse of provisional protection due to non-payment of fees |